In the section of our website you can find press releases and regulatory announcements as downloadable PDF files.
-
» Hikma’s diversified business delivers record sales and 36% earnings growth in 2009
17-Mar-201017 March 2010 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ DUBAI: HIK), the fast growing
multinational pharmaceutical group, today reports its preliminary results for the year ended 31 December 2009. -
» Hikma will release its 2009 preliminary results on Wednesday, March 17, 2010
01-Mar-2010LONDON, 1 March 2010 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (Nasdaq Dubai: HIK), the fast growing multinational pharmaceutical Group, will release its 2009 preliminary results on Wednesday, 17 March 2010. The company will host a presentation for analysts at 9 am and a live webcast of the presentation will be available on Hikma’s website. www.hikma.com
-
» Hikma announces partnership with BioCryst for its pandemic flu product
11-Jan-2010London, 11 January 2009: Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai: HIK), a leading speciality pharmaceutical company, announces that it has signed an exclusive agreement to represent BioCryst in respect of its anti-viral product peramivir for pandemic flu treatment stockpiling opportunities with governments in the Middle East and North Africa (‘MENA’) region.
-
» Hikma to present at the 2010 J.P. Morgan Healthcare Conference
06-Jan-2010Said Darwazah, Hikma’s Chief Executive Officer, will present at the 28th Annual J.P. Morgan Healthcare Conference, on Thursday, January 14, 2010, at 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time and 4:00 p.m. GMT.
-
» Hikma signs new agreement for Advagraf® with Astellas
04-Dec-2009Hikma signs new agreement for Advagraf® with Astellas
-
» Hikma Wins Best Company in an Emerging Market Award
19-Nov-2009Hikma Pharmaceuticals PLC is pleased to announce that it was the recipient of the ‘Best Company in an Emerging Market Award’ at the 5th Annual Scrip Awards held in London on 18 November 2009.
-
» Hikma Pharmaceuticals PLC – Interim Management Statement
12-Nov-2009Hikma Pharmaceuticals PLC (“Hikma”)(LSE: HIK)(NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products, is today updating the market on its current trading and financial position relating to the period from 1 July 2009 to date as required by the UK Listing Authority's Disclosure and Transparency Rules.
-
» Interim Results announcement for the 6 months ended 30th June 2009
27-Aug-2009Hikma reports today its Interim Results for the 6 months to 30th June 2009.
-
» Hikma Pharmaceuticals PLC – Interim Results
25-Aug-2009Hikma Pharmaceuticals PLC will be announcing its Interim Results announcement for the 6 months ended 30th June 2009 on Thursday, 27th August, 2009.
-
» Hikma signs licensing agreement with Faes Farma SA for anti-histamine Bilastine
17-Jul-2009Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai: HIK), a leading speciality pharmaceutical company, today announces that its subsidiary Hikma Pharmaceuticals LLC has signed a licensing agreement for the anti-histamine Bilastine with FAES FARMA, S. A., a Spanish pharmaceutical company, for the Middle East & North Africa (“MENA”) region.
